(VCEL) Vericel Ord - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.808m USD | Total Return: -16.1% in 12m
Avg Turnover: 22.5M
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
P/E ratio 82.3
Choppy
Tailwinds
Confidence
Vericel Corporation is a commercial-stage biopharmaceutical firm specializing in advanced cellular therapies and specialty biologics for the North American sports medicine and burn care sectors. The company’s portfolio centers on autologous cell therapies, which utilize a patients own cells to repair damaged tissue, reducing the risk of immunological rejection.
The company markets three primary products: MACI, a tissue-engineered scaffold for knee cartilage repair; Epicel, a permanent skin replacement for severe burns; and NexoBrid, a biological agent used for chemical debridement of thermal burn wounds. Operating within the biotechnology sub-industry, Vericel utilizes a high-complexity manufacturing model that requires specialized facilities to process patient biopsies into therapeutic implants.
Investors may find further insights into Vericel’s fundamental performance by reviewing the data available on ValueRay. Formerly known as Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts, and has been operational since 1989.
- MACI expansion into ankle and arthroscopic repair markets drives revenue growth
- NEXOBRID adoption rates in burn centers determine specialty biologic sales trajectory
- Manufacturing scale and automation efficiency dictate long-term gross margin expansion
- FDA regulatory approval timelines for pipeline extensions impact future valuation premiums
- Hospital capital spending and elective procedure volume influence sports medicine demand
| Net Income: 21.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.64 > 1.0 |
| NWC/Revenue: 67.41% < 20% (prev 66.32%; Δ 1.10% < -1%) |
| CFO/TA 0.13 > 3% & CFO 61.7m > Net Income 21.5m |
| Net Debt (-50.9m) to EBITDA (33.3m): -1.53 < 3 |
| Current Ratio: 5.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.8m) vs 12m ago 1.74% < -2% |
| Gross Margin: 74.84% > 18% (prev 0.73%; Δ 7.41k% > 0.5%) |
| Asset Turnover: 64.18% > 50% (prev 56.18%; Δ 8.00% > 0%) |
| Interest Coverage Ratio: 33.02 > 6 (EBITDA TTM 33.3m / Interest Expense TTM 637k) |
| A: 0.41 (Total Current Assets 244.1m - Total Current Liabilities 47.2m) / Total Assets 485.6m |
| B: -0.79 (Retained Earnings -382.6m / Total Assets 485.6m) |
| C: 0.05 (EBIT TTM 21.0m / Avg Total Assets 455.1m) |
| D: 2.75 (Book Value of Equity 356.2m / Total Liabilities 129.4m) |
| Altman-Z'' = 3.29 = A |
| DSRI: 1.12 (Receivables 72.4m/52.9m, Revenue 292.1m/238.5m) |
| GMI: 0.97 (GM 74.84% / 72.54%) |
| AQI: 1.24 (AQ_t 0.15 / AQ_t-1 0.12) |
| SGI: 1.22 (Revenue 292.1m / 238.5m) |
| TATA: -0.08 (NI 21.5m - CFO 61.7m) / TA 485.6m) |
| Beneish M = -2.74 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 35.15 with a total of 644,130 shares traded.
Over the past week, the price has changed by +5.15%,
over one month by +1.05%,
over three months by -9.20% and
over the past year by -16.07%.
Vericel Ord has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy VCEL.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 55.4 | 57.7% |
P/E Forward = 74.6269
P/S = 6.1893
P/B = 5.0748
Revenue TTM = 292.1m USD
EBIT TTM = 21.0m USD
EBITDA TTM = 33.3m USD
Long Term Debt = 80.4m USD (estimated: total debt 94.4m - short term 14.1m)
Short Term Debt = 14.1m USD (from shortTermDebt, last quarter)
Debt = 94.4m USD (from shortLongTermDebtTotal, last quarter) (leases 94.5m already included)
Net Debt = -50.9m USD (calculated: Debt 94.4m - CCE 145.3m)
Enterprise Value = 1.76b USD (1.81b + Debt 94.4m - CCE 145.3m)
Interest Coverage Ratio = 33.02 (Ebit TTM 21.0m / Interest Expense TTM 637k)
EV/FCF = 30.39x (Enterprise Value 1.76b / FCF TTM 57.8m)
FCF Yield = 3.29% (FCF TTM 57.8m / Enterprise Value 1.76b)
FCF Margin = 19.79% (FCF TTM 57.8m / Revenue TTM 292.1m)
Net Margin = 7.35% (Net Income TTM 21.5m / Revenue TTM 292.1m)
Gross Margin = 74.84% ((Revenue TTM 292.1m - Cost of Revenue TTM 73.5m) / Revenue TTM)
Gross Margin QoQ = 72.0% (prev 78.70%)
Tobins Q-Ratio = 3.62 (Enterprise Value 1.76b / Total Assets 485.6m)
Interest Expense / Debt = 0.67% (Interest Expense 637k / Debt 94.4m)
Taxrate = 4.94% (859k / 17.4m)
NOPAT = 20.0m (EBIT 21.0m * (1 - 4.94%))
Current Ratio = 5.18 (Total Current Assets 244.1m / Total Current Liabilities 47.2m)
Debt / Equity = 0.27 (Debt 94.4m / totalStockholderEquity, last quarter 356.2m)
Debt / EBITDA = -1.53 (Net Debt -50.9m / EBITDA 33.3m)
Debt / FCF = -0.88 (Net Debt -50.9m / FCF TTM 57.8m)
Total Stockholder Equity = 334.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.72% (Net Income 21.5m / Total Assets 485.6m)
RoE = 2.99% (Net Income TTM 21.5m / Total Stockholder Equity 717.5m)
RoCE = 2.64% (EBIT 21.0m / Capital Employed (Equity 717.5m + L.T.Debt 80.4m))
RoIC = 4.42% (NOPAT 20.0m / Invested Capital 452.5m)
WACC = 9.22% (E(1.81b)/V(1.90b) * Re(9.67%) + D(94.4m)/V(1.90b) * Rd(0.67%) * (1-Tc(0.05)))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.67 | Cagr: 0.23%
[DCF] Terminal Value 75.20% ; FCFF base≈52.1m ; Y1≈59.7m ; Y5≈87.9m
[DCF] Fair Price = 23.46 (EV 1.15b - Net Debt -50.9m = Equity 1.20b / Shares 51.1m; r=9.22% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.67 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 18.60% | SUE: 2.66 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=N/A | Revisions=N/A | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=+18.55% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=0.45 | Chg30d=+4.70% | Revisions=+20% | GrowthEPS=+41.2% | GrowthRev=+20.2%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=+5.84% | Revisions=+20% | GrowthEPS=+88.5% | GrowthRev=+17.0%
[Analyst] Revisions Ratio: +20%